Semaglutide, a GLP-1 receptor agonist, diminishes seizure severity and cognitive deficits by inhibiting the NLRP3 inflammasome pathway triggered by lipopolysaccharide (LPS) and nigericin, while also lowering lactate dehydrogenase (LDH) release from microglia [57]. This evidence concerns the gene GLP1R and Cognitive impairment.